Lonza and Entropic Unveil Scalable 96-Well 3D Human Skin Organoid Platform for Accelerated Screening

September 6, 2026

Scientist.com Switzerland

Overview

Lonza and Entropic have jointly developed a scalable 96-well 3D human skin organoid model, dramatically improving the efficiency of skin barrier function and injury screening. Utilizing Entropic’s ZYRALIX™ platform, this innovation rapidly generates self-assembling organoids that closely mimic in vivo skin structure and barrier function. This breakthrough offers a crucial bridge between simplistic 2D cultures and complex 3D models, enabling high-throughput screening of dermatological drug and product candidates at early development stages.

In Depth

Background

The fields of dermatological research, pharmaceutical development, and safety assessment for cosmetics and chemical products are increasingly demanding more human-specific and predictive in vitro models, driven by the growing recognition of ethical and scientific limitations associated with animal testing. While advanced 3D human skin models have emerged to address this critical need, challenges related to scalability and suitability for high-throughput screening have persisted. The collaborative effort between Lonza and Entropic introduces a compelling solution designed to overcome these long-standing hurdles, potentially establishing a new benchmark in the industry.

Key Findings

A collaborative endeavor between Lonza and Entropic has successfully produced a groundbreaking 96-well compatible 3D human skin organoid model, designed to dramatically accelerate screening for skin barrier function and injury. This self-assembling skin organoid, rapidly generated via the ZYRALIX™ platform, meticulously replicates in vivo skin structure and barrier function. The platform facilitates high-throughput screening at early development stages—a capability previously difficult with traditional models—promising significant reductions in time and cost across dermatological research, drug discovery, and the development of cosmetics and chemical products. Key aspects of this innovation include:

96-Well Compatible Scalability: Optimized for the 96-well plate format, the model offers critical high-throughput capacity and automation compatibility, enabling efficient, simultaneous evaluation of numerous compounds and conditions.
Leveraging ZYRALIX™ Platform: Entropic’s proprietary ZYRALIX™ platform serves as the foundational technology for rapidly and reproducibly generating these self-assembling skin organoids. This standardization ensures high consistency across batches and significantly enhances experimental reproducibility.
Replication of Structural Maturity and Barrier Function: Beyond structural replication, including key epidermal, dermal, and appendage structures, the organoids demonstrate vital barrier-related functions such as tight junction formation and resistance to transepidermal water loss. This functional fidelity is essential for accurate assessment of transdermal permeability and irritation responses.
Application as a Skin Injury Model: The model also serves as an effective in vitro platform for simulating various skin injuries, from burns and UV damage to chemical exposure. This capability advances research into wound healing mechanisms and enables robust screening of drug and product candidates for protective or regenerative effects.
Bridging Gaps with Traditional Models: Crucially, this 96-well compatible organoid model addresses a critical gap in dermatological research. Traditional 2D cell cultures lack physiological relevance, while existing full 3D skin models are often costly and time-consuming. The new organoid model strikes an optimal balance, offering superior physiological relevance compared to 2D cultures, combined with the experimental efficiency and scalability that full 3D models typically lack.

Strategic Significance & Outlook

This scalable 3D human skin organoid model is poised to revolutionize a diverse array of fields, encompassing the discovery of novel therapeutics for skin diseases, the development of advanced transdermal drug delivery systems, and the comprehensive safety assessment of cosmetics and household products. The ability to perform high-efficiency screening at early development stages will critically shorten product development cycles and reduce time-to-market costs. Looking ahead, the potential to generate skin organoids from patient-derived induced pluripotent stem cells (iPSCs) further opens avenues for personalized treatments in dermatology. This platform represents a significant leap forward, demanding attention from researchers, engineers, and investors due to its substantial market value and expansive application potential.

Source: https://www.scientist.com/webinar/advancing-skin-research-a-scalable-3d-human-skin-organoid-model-for-skin-barrier-function-and-injury-screening

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.